Flow resistance modulated aerosolized active agent delivery
AssigneeNovartis AG
InventorsAndrew Clark, Carlos Schuler, Steve Paboojian
Life of this patent
Estimating the term…
Abstract
The present invention is directed to methods and devices for delivering an active agent formulation to the lung of a human patient. The active agent formulation may be in dry powder form, it may be nebulized, or it may be in admixture with a propellant. The active agent formulation is delivered to a patient at a low inspiratory flow rate for an initial period of time to increase bioavailability of the active agent.
Claims16
A device for controlling the delivery of an aerosolized active agent to the lungs of a human patient, said device comprising a valve that provides a high flow resistance of at least 0.4 (cm H2O)1/2/SLM in the inhalation direction at the onset of the patient's inhalation and that subsequently opens during the inhalation to provide a lower flow resistance, wherein the lower flow resistance allows for a higher flow rate through the device.
A device for controlling the delivery of an aerosolized active agent to the lungs of a human patient, said device comprising a valve that provides a high flow resistance in the inhalation direction at the onset of the patient's inhalation and which corresponds to a flow rate of about 15 liters per minute or less and that subsequently opens during the inhalation to provide a lower flow resistance which corresponds to a higher flow rate.
A device for controlling the delivery of an aerosolized active agent to the lungs of a human patient, said device comprising a valve that is adapted to provide a first flow resistance in the inhalation direction at the onset of the patient's inhalation and that subsequently opens during the inhalation to provide a second flow resistance, the second flow resistance being less than the first flow resistance, wherein the second flow resistance allows for a higher flow rate.
Dependencies are inferred from the claim text.